Prognostic Value of Rab27B Nuclear Expression in Gastrointestinal Stromal Tumors

Table 1

Association of Rab27B expression with clinical parameters of GIST.

Groups	Number	Rab27B
		Low or no expression (%)	High expression (%)	Pearson	value
Total	162	74 (45.68)	88 (54.32)
Gender				0.012	0.913
Male	73	33 (45.21)	40 (54.79)
Female	89	41 (46.07)	48 (53.93)
Age				0.054	0.816
≤60 years	98	44 (44.90)	54 (55.10)
>60 years	62	29 (46.77)	33 (53.23)
Unknown	2	1	1
Tumor size				10.228	0.006*
<5 cm	40	21 (52.50	19 (47.50)
5–10 cm	78	41 (52.56)	37 (47.44)
≥10 cm	36	8 (22.22)	28 (77.78)
Unknown	8	4	4
Mitotic index (per 50 HPFs)				8.639	0.013*
0–5	67	38 (56.72)	29 (43.28)
6–10	54	24 (44.44)	30 (55.56)
>10	26	6 (23.08)	20 (76.92)
Unknown	15	6	9
Gross classification				0.184	0.668
Single nodule	11	4 (36.36)	7 (63.64)
Multiple nodules	18	8 (44.44)	10 (55.56)
Unknown	133	62	71
Tumor location				0.571	0.752
Stomach	81	37 (45.68)	44 (54.32)
Intestine	56	24 (42.86)	32 (57.14)
Others	23	12 (52.17)	11 (47.83)
Unknown	2	1	1
AFIP Miettinen risk classification				9.182	0.002*
Very low-low risk	34	20 (58.82)	14 (41.18)
Moderate-high risk	41	10 (24.39)	31 (75.61)
Unknown	87	44	43
Grade				9.703	0.021*
1	48	30 (62.50)	18 (37.50)
2	60	27 (45.00)	33 (55.00)
3	28	8 (28.57)	20 (71.43)
4	10	3 (30.00)	7 (70.00)
Unknown	16	6	10

; HPFs: high-power fields.